Matthew V. Ronan

Matthew V. Ronan

Auto-generated profile, based on publicly available information

Matthew V. Ronan

Department of Medicine VA Boston Healthcare System West Roxbury Massachusetts USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Health Affairs
Verified
Journal Article
Closed access
MRMatthew V. Ronan
Matthew V. Ronan
SHShoshana J. Herzig
Shoshana J. Herzig
Serious infection is a recognized complication of intravenous drug abuse and a major cause of morbidity and mortality among intravenous drug users. Trends in rates of serious infection and the asso...

7 August 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
JKJune-Ho Kim
June-Ho Kim
DFDanielle R. Fine
Danielle R. Fine
LLLily Li
Lily Li
SKSimeon D. Kimmel
Simeon D. Kimmel
LNLong H. Ngo
Long H. Ngo
SHShoshana J. Herzig
Shoshana J. Herzig
Patients with opioid use disorder (OUD) who are hospitalized for serious infections requiring prolonged intravenous antibiotics may face barriers to discharge, which could prolong hospital length of stay (LOS) and increase financial burden. We investigated differences in LOS, discharge disposition, and charges between hospitalizations for serious infections in patients with and without OUD. We utilized the 2016 National Inpatient Sample—a nationally representative database of all discharges from US acute care hospitals. The population of interest was all hospitalizations for infective endocarditis, epidural abscess, septic arthritis, or osteomyelitis. The exposure was OUD, and the primary outcome was LOS until discharge, assessed by using a competing risks analysis to estimate adjusted hazard ratios (aHRs). Adjusted odds ratio (aOR) of discharge disposition and adjusted differences in hospital charges were also reported. Of 95,470 estimated hospitalizations for serious infections (infective endocarditis, epidural abscess, septic arthritis, and osteomyelitis), the mean age was 49 years and 35% were female. 46% had Medicare (government-based insurance coverage for people age 65+ years), and 70% were non-Hispanic white. After adjustment for potential confounders, OUD was associated with a lower probability of discharge at any given LOS (aHR 0.61; 95% CI 0.59–0.63; p < 0.001). OUD was also associated with lower odds of discharge to home (aOR 0.38; 95% CI 0.33–0.43; p < 0.001) and higher odds of discharge to a post-acute care facility (aOR 1.85; 95% CI 1.57–2.17; p < 0.001) or patient-directed discharge (also referred to as “discharge against medical advice”) (aOR 3.47; 95% CI 2.80–4.29; p < 0.001). There was no significant difference in average total hospital charges, though daily hospital charges were significantly lower for patients with OUD. Limitations include the potential for unmeasured confounders and the use of billing codes to identify cohorts. Our findings suggest that among hospitalizations for some serious infections, those involving patients with OUD were associated with longer LOS, higher odds of discharge to post-acute care facilities or patient-directed discharge, and similar total hospital charges, despite lower daily charges. These findings highlight opportunities to improve care for patients with OUD hospitalized with serious infections, and to reduce the growing associated costs.

26 July 2022 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
SCSusan L. Calcaterra
Susan L. Calcaterra
RBRichard Bottner
Richard Bottner
MMMarlene Martin
Marlene Martin
HEHonora Englander
Honora Englander
ZWZoe M. Weinstein
Zoe M. Weinstein
SHShoshana J. Herzig
Shoshana J. Herzig

19 July 2024 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
PDF file
NANazima Allaudeen
Nazima Allaudeen
JAJoyce Akwe
Joyce Akwe
CACherinne Arundel
Cherinne Arundel
JBJoel C. Boggan
Joel C. Boggan
PCPeter Caldwell
Peter Caldwell
CGCraig G. Gunderson
Craig G. Gunderson

6 March 2024 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
MRMatthew V. Ronan
Matthew V. Ronan
KGKirsha S. Gordon
Kirsha S. Gordon
MSMelissa Ma Skanderson
Melissa Ma Skanderson
MKMichael Krug
Michael Krug
PGPatrick Godwin
Patrick Godwin
CGCraig G. Gunderson
Craig G. Gunderson
Objectives: Few studies describe contemporary alcohol withdrawal management in hospitalized settings or review current practices considering the guidelines by the American Society of Addiction Medicine (ASAM). Methods: We conducted a retrospective cohort study of patients hospitalized with alcohol withdrawal on medical or surgical wards in 19 Veteran Health Administration (VHA) hospitals between October 1, 2018, and September 30, 2019. Demographic and comorbidity data were obtained from the Veteran Health Administration Corporate Data Warehouse. Inpatient management and hospital outcomes were obtained by chart review. Factors associated with treatment duration and complicated withdrawal were examined. Results: Of the 594 patients included in this study, 51% were managed with symptom-triggered therapy alone, 26% with fixed dose plus symptom-triggered therapy, 10% with front loading regimens plus symptom-triggered therapy, and 3% with fixed dose alone. The most common medication given was lorazepam (87%) followed by chlordiazepoxide (33%), diazepam (14%), and phenobarbital (6%). Symptom-triggered therapy alone (relative risk [RR], 0.68; 95% confidence interval [CI], 0.57–0.80) and front loading with symptom-triggered therapy (RR, 0.75; 95% CI, 0.62–0.92) were associated with reduced treatment duration. Lorazepam (RR, 1.20; 95% CI, 1.02–1.41) and phenobarbital (RR, 1.28; 95% CI, 1.06–1.54) were associated with increased treatment duration. Lorazepam (adjusted odds ratio, 4.30; 95% CI, 1.05–17.63) and phenobarbital (adjusted odds ratio, 6.51; 95% CI, 2.08–20.40) were also associated with complicated withdrawal. Conclusions: Overall, our results support guidelines by the ASAM to manage patients with long-acting benzodiazepines using symptom-triggered therapy. Health care systems that are using shorter acting benzodiazepines and fixed-dose regimens should consider updating alcohol withdrawal management pathways to follow ASAM recommendations.

6 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LBLaura Burns
Laura Burns
BNBita Naimi
Bita Naimi
MRMatthew Ronan
Matthew Ronan
HXHuihong Xu
Huihong Xu
Horst Christian WeberHorst Christian Weber
Horst Christian Weber
Pancreatic neuroendocrine tumors, or pNETs, represent a rare and clinically heterogenous subset of pancreatic neoplasms. One such pNET, the insulinoma, is found to be malignant in just 4% of all insulinomas. Due to the exceedingly uncommon occurrence of these tumors, there is controversy regarding the optimal evidence-based management for these patients. We therefore report on a 70-year-old male patient admitted with 3 months of episodic confusion with concurrent hypoglycemia. The patient was found to have inappropriately elevated endogenous insulin levels during these episodes, and somatostatin-receptor subtype 2 selective imaging revealed a pancreatic mass metastatic to local lymph nodes, spleen, and the liver. Fine needle aspiration of pancreatic and liver lesions confirmed the diagnosis of a low grade pancreatic neuroendocrine tumor. Molecular analysis of tumor tissue revealed a novel mutational profile consistent with pNET. The patient was initiated on octreotide therapy. However, treatment with octreotide alone demonstrated limited efficacy in controlling the patient’s symptoms, prompting consideration of other therapies.